Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042821 | 0.80 | KDM4E (0.36) | PARP1KDM4EHPGDALDH1A1 | |
| SCHEMBL15045455 | 0.71 | PARP1 (0.35) | CA1CA2PARP1TRPA1KDM4E | |
| SCHEMBL283346 | 0.67 | TRPA1 (0.50) | CA1CA2PARP1TRPA1 | |
| SCHEMBL31586332 | 0.67 | TRPA1 (0.50) | CA1CA2PARP1TRPA1 | |
| SCHEMBL15045569 | 0.67 | TYMS (0.51) | TYMSKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL15045578 | 0.67 | PARP1 (0.34) | CA1CA2PARP1TRPA1ALDH1A1 | |
| SCHEMBL5995568 | 0.67 | CA1 (0.42) | CA1CA2PARP1TRPA1ALDH1A1 | |
| SCHEMBL15042877 | 0.65 | DRD2 (0.33) | PARP1KDM4E | |
| SCHEMBL401773 | 0.63 | TRPA1 (0.40) | CA1CA2PARP1TRPA1ALDH1A1 | |
| SCHEMBL27986120 | 0.62 | PARP1 (0.41) | CA1CA2PARP1TRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | TYMS 747/4885CA1 1649/4885CA2 3902/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | TYMS 249/4885CA1 3169/4885CA2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.